Feedback
Settings

Settings

Goto Application

1. WO2022110962 - NEUTRALIZING ANTIBODY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME TYPE II CORONAVIRUS (SARS-COV-2)

Submit observation
PermaLink
Publication Number WO/2022/110962
Publication Date 02.06.2022
International Application No. PCT/CN2021/116808
International Filing Date 12.10.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
C12N 15/70 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
C12N 1/21 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • 苏州大学 SOOCHOW UNIVERSITY [CN]/[CN]
Inventors
  • 刘密 LIU, Mi
  • 王义鹏 WANG, Yipeng
  • 刁璐 DIAO, Lu
  • 马琳 MA, Lin
  • 章铭辉 ZHANG, Minghui
  • 镇学初 ZHEN, Xuechu
  • 龙亚秋 LONG, Yaqiu
Agents
  • 苏州市中南伟业知识产权代理事务所（普通合伙） CENTRAL SOUTH WELL INTELLECTUAL PROPERTY OFFICE
Priority Data
202011339257.125.11.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) NEUTRALIZING ANTIBODY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME TYPE II CORONAVIRUS (SARS-COV-2)
(FR) ANTICORPS NEUTRALISANT DIRIGÉ CONTRE LE CORONAVIRUS DE TYPE II DU SYNDROME RESPIRATOIRE AIGU SÉVÈRE (SARS-COV-2)
(ZH) 抗严重急性呼吸系统综合征II型冠状病毒SARS-COV-2的中和抗体
front page image
Abstract
(EN) Disclosed is a neutralizing antibody against severe acute respiratory syndrome type II coronavirus (SARS-CoV-2), which belongs to the technical field of biomedicine. Peripheral immune cells are extracted from the blood of a patient who has recovered from COVID-19, and B cells that can bind to a novel coronavirus antigen protein-spike protein are screened therefrom. Analysis is then performed on single B cells producing antibodies at the single-cell level, thereby obtaining gene sequences which are in the B cells and encode the variable region heavy and light chains of the neutralizing antibody. These sequences can be used for the in vitro re-construction and expression of the neutralizing antibody that can neutralize novel coronavirus and are expected to be used for the treatment and prevention of diseases such as pneumonia caused by the novel coronavirus.
(FR) L'invention concerne un anticorps neutralisant dirigé contre le coronavirus de type II du syndrome respiratoire aigu sévère (SARS-CoV-2), relevant du domaine technique de la biomédecine. Des cellules immunitaires périphériques sont extraites du sang d'un patient qui s'est remis du COVID-19, et des cellules B qui peuvent se lier à une nouvelle protéine de spicule de protéine d'antigène du coronavirus sont criblées à partir de celles-ci. L'analyse est ensuite effectuée sur des cellules B uniques produisant des anticorps au niveau de la cellule unique, ce qui permet d'obtenir des séquences de gènes qui se trouvent dans les cellules B et codent les chaînes lourdes et légères de région variable de l'anticorps neutralisant. Ces séquences peuvent être utilisées pour la nouvelle construction et l'expression in vitro de l'anticorps neutralisant qui peut neutraliser un nouveau coronavirus et sont censées être utilisées pour le traitement et la prévention de maladies telles que la pneumonie provoquée par le nouveau coronavirus.
(ZH) 公开了一种抗严重急性呼吸系统综合征II型冠状病毒SARS-COV-2的中和抗体，属于生物医药技术领域。从COVID-19康复患者血液中提取外周免疫细胞，并从中筛选可以和新冠病毒抗原蛋白-刺突蛋白结合的B细胞，然后对以生产抗体的单个B细胞在单细胞水平上进行分析，获得了B细胞内编码中和抗体可变区重链和轻链的基因序列。这些序列即可用来体外重新构建和表达可中和新冠病毒的中和抗体，有望用于新冠病毒所引起的肺炎等疾病的治疗和预防。
Related patent documents
CN112442120
CN113801223
Latest bibliographic data on file with the International Bureau
# -